(Q30375051)

21 June 2017

1 reference

title

Correlates of protection: novel generations of influenza vaccines. (English)

1 reference

21 June 2017

1

Guus F Rimmelzwaan

1 reference

21 June 2017

2

Janet E McElhaney

1 reference

PubMed ID

19230158

21 June 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

21 June 2017

1 reference

21 June 2017

26 Suppl 4

1 reference

21 June 2017

D41-4

1 reference

Mapping the antigenic and genetic evolution of influenza virus

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Induction of Partial Immunity to Influenza by a Neuraminidase-specific Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Protection of mice with recombinant influenza virus neuraminidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Evaluation of a Neuraminidase-Specific Influenza A Virus Vaccine in Children: Antibody Responses and Effects on Two Successive Outbreaks of Natural Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Modified M2 proteins produce heterotypic immunity against influenza A virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Transepithelial transport of immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Cytotoxic T-cell immunity to influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Avian Influenza A (H5N1) Age Distribution in Humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Functional compensation of a detrimental amino acid substitution in a cytotoxic-T-lymphocyte epitope of influenza a viruses by comutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Full restoration of viral fitness by multiple compensatory co-mutations in the nucleoprotein of influenza A virus cytotoxic T-lymphocyte escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by using virus-specific CD8+ T-cell clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Granzyme B: a marker of risk for influenza in institutionalized older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

T cell responses are better correlates of vaccine protection in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

Immunity to influenza in older adults with chronic obstructive pulmonary disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.043

10.1016/J.VACCINE.2008.07.043

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

19230158